Related Experiment Video

Updated: Mar 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

[Alternative antiandrogen therapy for castration-resistant prostate cancer]

Hiroyoshi Suzuki, Takanobu Utsumi, Takumi Endo

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |June 28, 2016
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Murine Prostate Micro-dissection and Surgical Castration
    08:49

    Murine Prostate Micro-dissection and Surgical Castration

    Published on: May 11, 2016

    48.0K
    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.0K

    Related Experiment Videos

    Last Updated: Mar 18, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    14.0K
    Murine Prostate Micro-dissection and Surgical Castration
    08:49

    Murine Prostate Micro-dissection and Surgical Castration

    Published on: May 11, 2016

    48.0K
    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    1.0K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    9.1K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.9K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    1.5K

    Articles linked to this work by shared authors, journal, and citation graph.

    Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial.

    Journal of radiation research·2026

    [A QUESTIONNAIRE SURVEYON TREATMENT SELECTION FOR PATIENTS WITH ADVANCED PROSTATE CANCER IN JAPAN].

    Hinyokika kiyo. Acta urologica Japonica·2026

    Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI-PARP-Radioligand Era.

    Cancers·2026

    Advances in Precision Diagnostics and Personalized Therapeutics for Prostate Cancer: An Integrated Precision Continuum from Risk-Adapted Detection to Biomarker-Directed Therapy and Dynamic Monitoring.

    Cancers·2026

    Soft tissue chondroma of the thumb mimicking a glomus tumor.

    Dermatology reports·2026

    EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

    Prostate cancer and prostatic diseases·2026

    Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Association between ineffective health self-management and severe radiodermatitis: Cohort study.

    International journal of nursing knowledge·2026

    Systematic review: Stereotactic Body Radiation Therapy for Pancreatic Cancer: Evaluating its Efficacy, Safety, and Future Prospects.

    The British journal of radiology·2026

    A prospective, randomized study comparing different therapeutic modalities for acute adenoviral conjunctivitis.

    Indian journal of ophthalmology·2026

    Laser and Light-Based Therapies in Inflammatory Dermatoses: A Systematic Review of Safety, Efficacy, and Adverse Effects to Inform Cosmetic Use.

    Lasers in surgery and medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us